Achieving Appropriate Access to High Quality Care for the Treatment of Primary Immunodeficiency Web Activity

• Release Date: December 1, 2022
• Expiration Date: May 31, 2024
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

Expert Faculty Author:

James T. Kenney, RPh, MBA President JTKenney, LLC Click here for biography Blachy J. Dávila Saldaña, MD Attending Physician, Division of Blood and Marrow Transplantation Director, Combined Immunodeficiency BMT Clinic Fellowship Director, Bone Marrow Transplant and Cell Therapy Children's National Hospital Associate Professor of Pediatrics George Washington University School of Medicine and Health Sciences Click here for biography

Target Audience
The primary target audience for this initiative consists of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors, medical directors, and other managed health care professionals.

Statement of Need/Program Overview
Primary immunodeficiency (PI) affects >500,000 people in the United States, with a significant proportion of individuals with milder immune system defects suspected as not being formally diagnosed. The occult nature of PI symptoms and an overwhelming cache of potential differential diagnoses result in frequently delayed diagnoses and misdiagnoses, culminating in a lack of access to effective treatment and worsening outcomes. Rapid growth within PI’s diagnostic and therapeutic space is coupled with distinctly higher claims among patients whose diagnosis and appropriate treatment are delayed. These challenges are compounded for managed care professionals managing rising healthcare expenditures and the specialty drug trend. By instituting applicable coverage criteria, these stakeholders can improve the recognition and management of PI within their plan populations and ultimately impact total costs.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe the potential signs and symptoms of primary immunodeficiency (PI) in addition to predominant screening and diagnostic modalities
• Assess available therapeutic options for PI based on disease type and patient characteristics
• Characterize the adverse effect of excess cost-sharing on and prohibitive coverage criteria on patient access and adherence
• Implement medical and pharmacy benefit design strategies that improve access to therapy and manage costs with evidence-based clinical care for PI

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM), the Immune Deficiency Foundation (IDF), and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity.

Continuing Pharmacy Education
The Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-472-H01-P
Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM, IDF, and Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.